Australia: Kazia completes equity financing round

Kazia Therapeutics, an oncology-focused drug development company, has concluded an equity financing round totalling A$7.106m (US$4.78m) split A$4.5m raised from existing sophisticated and institutional investors and A$2.606m from existing shareholders via a Share Purchase Plan Proceeds will be applied to the company’s R&D pipeline, which comprises two assets in nine clinical trials. “The proceeds of…

You must be a HMI Subscriber to view this content.

Subscribe Now »